Simulating the Effect of Spectroscopic MRI as a Metric for Radiation Therapy Planning in Patients with Glioblastoma.

J. Scott Cordova, Emory University
Shravan Kandula, Emory University
Saumya Gurbani, Emory University
Jim Zhong, Emory University
Mital Tejani, Emory University
Oluwatosin Kayode, Emory University
Kirtesh Patel, Emory University
Roshan Prabhu, Levine Cancer Institute
Eduard Schreibmann, Emory University
Ian Crocker, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: Tomography : a journal for imaging research
Volume: Volume 2, Number 4
Publisher: Grapho Publications, LLC. | 2016-12, Pages 366-373
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.18383/j.tom.2016.00187
Permanent URL: https://pid.emory.edu/ark:/25593/rwks

Final published version: http://dx.doi.org/10.18383/j.tom.2016.00187

Copyright information:
© 2016 The Authors. Published by Grapho Publications, LLC.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed November 23, 2019 10:20 AM EST
Simulating the Effect of Spectroscopic MRI as a Metric for Radiation Therapy Planning in Patients with Glioblastoma

J. Scott Cordova1, Shravan Kandula2,3, Saumya Gurbani1,6, Jim Zhong2, Mital Tejani2, Oluwatosin Kayode2, Kirtesh Patel2, Roshan Prabhu4, Eduard Schreibmann2, Ian Crocker2,5, Chad A. Holder1, Hyunsuk Shim1,2,5,6, and Hui-Kuo Shu2,5

1Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia; 2Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia; 3Florida Hospital Medical Group, Radiation Oncology Associates, Orlando, Florida; 4SE Radiation Oncology Group, Levine Cancer Institute, Charlotte, North Carolina; 5Winship Cancer Institute, Atlanta, Georgia; and 6Department of Biomedical Engineering, GA Institute of Technology, Atlanta, Georgia

Corresponding Authors:
Hui-Kuo Shu, MD, PhD
Department of Radiation Oncology, Emory University School of Medicine, 1365 Clifton Road, Atlanta, GA 30322;
E-mail: hgs@emory.edu; and
Hyunsuk Shim, PhD
E-mail: hshim@emory.edu

Key Words: glioblastoma, magnetic resonance spectroscopy, spectroscopic MRI, radiation therapy planning, metabolic regions-of-interest
Abbreviations: Radiation therapy (RT), magnetic resonance imaging (MRI), spectroscopic MRI (sMRI), choline to N-Acetylaspartate (Cho/NAA), contrast-enhanced T1-weighted (CE-T1w), fluid-attenuated inversion recovery (FLAIR), magnetic resonance spectroscopic imaging (MRSI), magnetic resonance spectroscopy (MRS), gross target volumes (GTVs), clinical target volumes (CTVs), planning target volumes (PTVs), Dice similarity coefficient (DICE), isodose lines (IDs)

INTRODUCTION
Optimal targeting of glioblastoma (GBM) for radiation therapy (RT) using computed tomography (CT) and magnetic resonance imaging (MRI) remains challenging because of the tumor’s infiltrative nature. Traditionally, 2 RT target volumes are created on the planning CT as follows: one defining enhancing tissue and the resection cavity on contrast-enhanced T1-weighted MRI and another defining signal changes on a T2-weighted, fluid-attenuated inversion recovery (FLAIR) sequence. However, histological analyses indicate that these sequences fail to capture the true extent of disease because of infiltrative, nonenhancing tumor (1-5). In addition, anatomic MRI provides limited information on the physiological state and biochemical activity of a viable tumor (4). The inability to accurately identify active tumor using conventional neuroimaging remains a limiting factor in GBM RT planning.

Proton magnetic resonance spectroscopic imaging (MRSI) is a molecular imaging technique that maps the metabolism of native small molecules to tumor regions in vivo without exogenous tracers (6, 7). Studies have shown that the addition of magnetic resonance spectroscopy (MRS) to tumor targeting allows identification of unique metabolic regions of interest with
Spectroscopic MRI in RT Planning for GBM

CONVENTIONAL AND sMRI TARGET VOLUME DEFINITIONS

Conventional treatment volumes were generated using VelocityAI by radiation oncologists (SK and HKS). Gross target volumes (GTVs) 1 and 2 defined the T2-weighted/FLAIR abnormality and contrast-enhancing tissue/resection cavity, respectively, whereas clinical target volumes (CTVs) 1 and 2 defined these GTVs with 0.7- and 0.5-cm modified margins, respectively. The planning target volumes (PTVs) 1 and 2 consisted of the CTV1 and CTV2 with 0.3-cm margins, respectively. The PTV1 was prescribed to 51 Gy (10 patients) or 54 Gy (1 patient) in 30 fractions. PTV2 was prescribed to 60 Gy in 30 fractions for all patients using a simultaneous integrated boost technique.

sMRI-modified target volumes were generated using Cho/NAA maps to account for tumor infiltration into the surrounding tissue (13). Cho/NAA thresholds depicting 1.5-, 1.75-, and 2.0-fold increases were segmented, representing absolute Cho/NAA ratios of 0.9–1.2, which have been shown to be pathological (17–19). GTV2 and CTV2 volumes for the sMRI-modified plans were generated as described for the conventional plans. Each Cho/NAA segmentation was merged with the conventional CTV2 to create an “sMRI_CTV2” to more sensitively account for microscopic disease (13). An additional 0.3-cm margin was added to create the “sMRI_PTV2.” For replanning, each sMRI_CTV2 was merged with CTV1 to create “sMRI_CTV1,” to which a 0.3-cm margin was added to generate “sMRI_PTV1.”

DATA ANALYSIS, REPLANNING, AND RECURRENCE EVALUATION

Each Cho/NAA segmentation and target volume was imported to Matlab (The MathWorks, Inc.) as a Digital Imaging and Communications in Medicine (DICOM)-RT structure with coregistered CE-T1w images and rasterized into the CE-T1w image space. For each threshold, the sMRI_CTV2 and CTV2 were compared in terms of absolute volume and spatial overlap using the Dice similarity coefficient (DICE) (20, 21). In addition, the percent volume of each Cho/NAA segmentation extending beyond the CTV1, CTV2, and respective 100% prescription isodose lines (IDLs) was calculated.

sMRI-modified RT plans were replanned in the Eclipse Treatment Planning System (Varian Medical Systems) by medical dosimetrists using sMRI-modified target volumes to evaluate target coverage and organ-at-risk dose. The planning goal was set for 100% of the dose to cover 95% of the target volume, while limiting the maximum dose to the brainstem, optic chi-

METHODOLOGY

Patients

Newly diagnosed, pathologically-confirmed patients with GBM were enrolled in an institutional review board-approved clinical trial. All patients underwent an sMRI scan ≤7 days before standard-of-care chemoradiation, which consisted of a 60 Gy dose (30 fractions of 2 Gy) with concomitant and adjuvant temozolomide. Patients were scanned following surgery (eg, resection or biopsy) and before starting chemoradiation. Patients were at least 18 years of age, had a Karnofsky Performance Status score of ≥70, and were both willing and able to sign informed consent forms. Patients with MRI-incompatible implants, medical conditions compromising RT tolerance, or receiving investigational agents were excluded.

sMRI Data Acquisition and Processing

Whole-brain, 3-dimensional echo-planar spectroscopic imaging was conducted on a 3 T MRI scanner with a 32-channel head coil array (TIM/TRIO, Siemens Medical Solutions, Erlangen, Germany). The head coil was securely attached and padded with foam blocks to reduce patient motion. Within the Syngo software, first-order shims were manually optimized to a waterline width of ≤25 Hz, and lipid signal was nulled using outer volume suppression with manually placed saturation bands. Tissue water signal was collected in an interleaved manner with the metabolite data for signal normalization and image registration. The sequence time was 17 minutes, plus an additional 2 minutes for manual shimming. Spectroscopic data were processed using the Metabolite Imaging and Data Analysis System (MIDAS) to obtain maps with a nominal voxel size of 4.4 × 4.4 × 5.6 mm³ at acquisition; postprocessing yields an effective voxel volume of 1 mL (14, 15). Metabolite maps included choline, creatine, N-Acetylaspartate, and Cho/NAA. These maps were imported into VelocityAI (Varian Medical Systems) for registration to the CE-T1w and T2-weighted/FLAIR images and upsampled into the clinical MRI image space using trilinear interpolation (16). As metabolite levels fluctuate with age, gender, and location, signal standardization was accomplished by scaling maps using the mean metabolite value of contralateral normal–appearing white matter to generate fold-normal–fold measures of metabolic abnormality (14). Throughout this paper, “Cho/NAA values” refers to the fold-increase of the ratio as compared with the mean ratio in normal–appearing white matter.

significant clinical consequence (ie, regions of tumor progression) (8–12). Moreover, recently, it was shown that the choline to N-Acetylaspargate ratio (Cho/NAA), a marker describing glial cell proliferation, correlates with tumor infiltration, progression-free survival, and contrast enhancement at recurrence in GBM (13). Thus, Cho/NAA regions of interest deserve consideration during target planning, and may be of use if effectively integrated into image guidance.

However, technical limitations have hindered the use of MRS in RT planning. Sequence-specific limitations including poor spatial resolution and limited brain coverage obscure the margins of metabolic abnormalities and prohibit visualization of infiltration into the surrounding brain tissue. This prevents accurate and complete delineation of tumor infiltration, curbing the value of metabolic data in target planning for GBM. In addition, there is a paucity of clinical decision support software for the analysis, visualization, and management of spectroscopic data. Consequently, spectroscopic processing requires a skilled user to evaluate spectra and manually transfer data between platforms, resulting in a complex workflow that is impractical for clinical RT. To address these limitations, we have developed an image acquisition and processing pipeline based on previously established state-of-the-art, high-resolution spectroscopic MRI (sMRI) and automated analysis tools to allow the addition of whole-brain metabolite maps to RT planning (14). Herein, we describe this sMRI workflow, evaluate its integration into RT planning, and determine the degree to which it modifies RT target volumes in GBM.
asm, and optic nerves to <54 Gy. A maximum point dosage of 60 Gy to the brainstem with no more than 10% above 54 Gy was a hard constraint. Coverage of the PTV60 to 90% was allowable in cases where the brainstem and tumor were in close proximity.

Follow-up imaging was analyzed to determine the coverage of contrast-enhancing recurrent tumor by conventional and sMRI-modified plans. Follow-up MRI scans acquired at 2- to 3-month intervals were evaluated by radiation oncologists for tumor progression using the RANO criteria (22). In patients with progression (confirmed with subsequent imaging or biopsy), recurrent tumor was segmented, confirmed by a neuroradiologist, and compared with the treatment plans to evaluate recurrent tumor coverage.

Statistical Methods
Statistical analyses were performed with the Matlab Statistics and Machine Learning Toolbox with significance set at $P \leq .05$. Differences in conventional and sMRI-modified target volumes and percentage of recurrence outside of CTV2 were evaluated using one-sided paired $t$ tests. Target coverage and brainstem doses were evaluated using one-way analysis of variance. Differences in DICE indices were evaluated using one-sided $t$ tests for population means (set at 1.0) with unknown variances.

RESULTS
Volumetric and Spatial Analysis
Whole-brain sMRI data were obtained from 11 patients between July 2014 and March 2015 (Supplemental Table 1) and processed using the pipeline described above (also shown in Figure 1). Of note, a single patient (patient 8) had an unresectable tumor and did not undergo surgical resection before chemoradiation. An example of MRI, Cho/NAA, and RT dosage plan overlays in a patient with superimposed CTVs and Cho/NAA thresholds can be found in Figure 2. The mean volume percentage increase in sMRI_CTV2 was 74.1%, 42.2%, and 25.1% for Cho/NAA thresholds of 1.5-, 1.75-, and 2.0-fold, respectively (Supplemental Table 2). The 1.5-fold sMRI_CTV2 volume increased significantly, although 1.75- and 2.0-fold sMRI_CTV2s did not. MRI_CTV1 also increased, but to a smaller extent (14.1%, 7.88%, and 5.02% at 1.5-, 1.75-, and 2.0-fold, respectively) and not significantly ($P = .96$). Significantly decreased spatial overlap was noted between the conventional CTV and all Cho/NAA segmentations with mean DICE scores of 0.51, 0.53, and 0.51 (1.5-, 1.75-, and 2.0-fold, respectively; Figure 3A; Supplemental Table 2). The mean Cho/NAA abnormality extending outside of the 100% IDL of PTV1 and PTV2 was 12.4 cm$^3$ and 41.1 cm$^3$, 5.36 cm$^3$ and 22.2 cm$^3$, and 2.37 cm$^3$ and 12.7 cm$^3$ for 1.5-, 1.75-, and 2.0-fold thresholds, respectively (Supplemental Table 3). The percentage of sMRI volume extending beyond the 60 Gy IDL was significantly increased for each Cho/NAA threshold (Figure 3B); however, for the 51 Gy IDL, only the 1.5-fold threshold was significant ($P = .03$).

Replanning
Table 1 details target coverage and maximum brainstem dose for each patient. Replanning was successful and clinically acceptable for all patients at each Cho/NAA threshold. In all plans, the maximum dosage to the optic nerves and chiasm met specified
Figure 2. Contrast-enhanced T1-weighted (CE-T1W), choline to N-Acetylaspartate (Cho/NAA) map, and dose fields for a patient with a frontal glioblastoma (GBM) who received standard chemoradiation (patient 3). Cho/NAA abnormalities extended medially and posteriorly from the contrast-enhancing border, implying contralateral infiltration (A–C). A region of 2.0-fold Cho/NAA increase [red contour] falls outside the clinical target volumes (CTVs)2 (turquoise contour) and CTV1 (green contour) near the midline (D). A comparison of the cumulative RT dose with 2.0-fold (blue contour) and 1.75-fold (white contour) Cho/NAA changes shows a large portion of metabolic abnormality falling outside of the region receiving 60 Gy (E and F).

Figure 3. Spatial and volumetric comparison of sMRI abnormalities and plans with those generated using conventional imaging. The spatial overlap for each Cho/NAA threshold with the CTV2 was shown to be significantly different from unity (A), with significant volumes of each threshold falling outside of the 60 Gy IDLs (B). sMRI-modified plans exhibited significantly higher coverage of contrast-enhancing tumor at recurrence than conventional plans (C). DICE and metabolic volumes outside of 60 Gy isodose lines (IDLs) were compared with unity and the planning target volume (PTVs)2 outside of the 60 Gy IDLs for conventional plans, respectively.

constraints. The average target volume coverage for sMRI_PTV 1 and 2 was not significantly different from conventional plans ($P = .172$ and $0.110$, respectively). Only 2 patients’ revised plans did not closely meet the desired target coverage (for PTV2 [60 Gy]) because of brainstem proximity. However, PTV2 coverage in the conventional plan was not achieved in either case. The
maximum brainstem dose was significantly higher in sMRI-modified plans, likely because of the substantial increase in the dosage for patients 3 and 11 (13.0 and 7.3 Gy and 59.8 and 58.4 Gy, respectively). However, the brainstem received ≤60 Gy in all cases.

**Recurrent Tumor Coverage Analysis**

Median follow-up time was 11.7 months, during which tumor recurrence was observed in 7 of 11 patients, with a median time-to-recurrence of 3.3 months (interquartile range, 2.48 mo; range, 0.97–8.8 mo). Preliminary analysis of recurrence location shows that in 6 of 7 patients, sMRI-modified CTVs encompassed regions of contrast-enhancing tumor at recurrence that was not targeted with conventional plans. In these patients, the coverage of contrast enhancement at recurrence was significantly larger for 1.5-, 1.75-, and 2.0-fold Cho/NAA sMRI_CTVs on average (92.4%, 90.5%, and 88.6%, respectively) than for conventional CTV (82.5%) (Figure 3C). Representative examples can be found in Figure 4.

More than 95% of recurrent tumors fell within the 60 Gy IDL of the original plan in 5 out of 7 patients. However, patients 9 and 11 (Figure 5) exhibited a substantial proportion of contrast enhancement outside of the 60 Gy (15.8% and 31.9%, respectively) and 57 Gy IDLs (4.4% and 28.1%, respectively). If contrast enhancement at recurrence was known and considered as a target volume in planning, 95% of the recurrence would not receive 60 Gy and 100% of the recurrence would not receive 57 Gy using the conventional plan in either case. However, replanning with sMRI_CTVs increased the 60 and 57 Gy coverage of recurrent tumor to meet these planning objectives. Using 1.5-, 1.75-, and 2.0-fold Cho/NAA sMRI_CTVs, for patient 9, 96.1%, 92.4%, and 87.4% of recurrent tumors received 60 Gy, whereas 99.1%, 98.9%, and 97.1% tumors received 57 Gy, respectively. Similarly, for patient 11, 97.6%, 95.3%, and 92.5% of recurrent tumors received 60 Gy, whereas 99.0%, 97.3%, and 96.4% received 57 Gy, respectively.

**DISCUSSION**

Several groups have reported that spectroscopy identifies regions of tumor infiltration beyond contrast enhancement, even within edema (23–27). In addition, a study recently published by our group found Cho/NAA to be highly correlated with the presence of neoplastic cells in patients with GBM receiving surgery (28). As this ratio comprises markers describing membrane lipid biosynthesis (eg, choline) and neuronal integrity (eg, N-Acetylaspartate), peritumoral Cho/NAA elevations indicate the presence of a highly proliferative, non-neuronal cell population that is highly suggestive of tumor infiltration. In this work, we describe a clinical workflow that enables the incorporation of the Cho/NAA ratio from sMRI into RT planning to improve target volume definition in patients with GBM. We also show that the addition of this metabolic information can significantly alter RT treatment plans in such a way that may improve local control.

MRSI has previously been integrated in RT planning; however, these reports exhibit a number of technical limitations (3, 8–12, 29). First, the partial volume effects and limited coverage of the low-resolution, limited field-of-view techniques used severely limit the use of MRSI clinically. Second, none of these studies uses systematic methods for normalizing spectroscopic

### Table 1. Target Coverage and Brainstem Dosages for Conventional and sMRI-modified RT Plans

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>Median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target volume coverage (%) of PTV1 by prescription dosage (54 Gy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conv_PTV1</td>
<td>98.0</td>
<td>98.5</td>
<td>100.0</td>
<td>99.9</td>
<td>99.5</td>
<td>94.6</td>
<td>97.9</td>
<td>99.9</td>
<td>97.5</td>
<td>98.8</td>
<td>99.9</td>
<td>98.80</td>
</tr>
<tr>
<td>sMRI_PTV1(1.50-fold)</td>
<td>99.5</td>
<td>99.9</td>
<td>100.0</td>
<td>99.9</td>
<td>100.0</td>
<td>98.7</td>
<td>99.1</td>
<td>99.4</td>
<td>98.3</td>
<td>100.0</td>
<td>99.9</td>
<td>99.90</td>
</tr>
<tr>
<td>sMRI_PTV1(1.75-fold)</td>
<td>99.9</td>
<td>100.0</td>
<td>100.0</td>
<td>99.9</td>
<td>99.9</td>
<td>98.7</td>
<td>99.1</td>
<td>96.7</td>
<td>98.1</td>
<td>100.0</td>
<td>99.9</td>
<td>99.90</td>
</tr>
<tr>
<td>sMRI_PTV1(2.0-fold)</td>
<td>99.9</td>
<td>100.0</td>
<td>100.0</td>
<td>99.9</td>
<td>99.7</td>
<td>97.8</td>
<td>98.8</td>
<td>99.2</td>
<td>99.1</td>
<td>99.7</td>
<td>99.9</td>
<td>99.70</td>
</tr>
<tr>
<td>Target volume coverage (%) of PTV2 by prescription dosage (60 Gy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conv_PTV2</td>
<td>98.0</td>
<td>96.8</td>
<td>97.9</td>
<td>86.2</td>
<td>98.9</td>
<td>96.5</td>
<td>98.9</td>
<td>98.7</td>
<td>89.5</td>
<td>99.9</td>
<td>94.6</td>
<td>98.00</td>
</tr>
<tr>
<td>sMRI_PTV2(1.50-fold)</td>
<td>91.0</td>
<td>93.5</td>
<td>95.5</td>
<td>83.0</td>
<td>94.7</td>
<td>94.5</td>
<td>95.0</td>
<td>94.6</td>
<td>80.0</td>
<td>95.0</td>
<td>95.0</td>
<td>94.60</td>
</tr>
<tr>
<td>sMRI_PTV2(1.75-fold)</td>
<td>95.0</td>
<td>94.9</td>
<td>95.0</td>
<td>84.0</td>
<td>95.4</td>
<td>94.3</td>
<td>95.0</td>
<td>95.0</td>
<td>85.1</td>
<td>95.1</td>
<td>94.1</td>
<td>95.00</td>
</tr>
<tr>
<td>sMRI_PTV2(2.0-fold)</td>
<td>96.0</td>
<td>95.0</td>
<td>95.0</td>
<td>86.0</td>
<td>95.9</td>
<td>94.0</td>
<td>95.0</td>
<td>94.9</td>
<td>91.3</td>
<td>95.5</td>
<td>94.8</td>
<td>95.00</td>
</tr>
<tr>
<td>Brainstem maximum dosage (Gy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conv_PTV1</td>
<td>53.5</td>
<td>55.0</td>
<td>13.0</td>
<td>59.3</td>
<td>52.8</td>
<td>53.9</td>
<td>59.4</td>
<td>58.3</td>
<td>58.0</td>
<td>52.9</td>
<td>7.3</td>
<td>53.90</td>
</tr>
<tr>
<td>sMRI_PTV1(1.50-fold)</td>
<td>58.9</td>
<td>59.9</td>
<td>59.8</td>
<td>57.9</td>
<td>57.8</td>
<td>59.4</td>
<td>58.7</td>
<td>59.6</td>
<td>58.3</td>
<td>58.8</td>
<td>58.0</td>
<td>58.80</td>
</tr>
<tr>
<td>sMRI_PTV1(1.75-fold)</td>
<td>58.7</td>
<td>58.8</td>
<td>58.1</td>
<td>58.9</td>
<td>58.1</td>
<td>59.2</td>
<td>59.0</td>
<td>59.4</td>
<td>59.2</td>
<td>58.4</td>
<td>58.4</td>
<td>58.80</td>
</tr>
<tr>
<td>sMRI_PTV1(2.0-fold)</td>
<td>58.7</td>
<td>59.2</td>
<td>55.4</td>
<td>58.2</td>
<td>57.8</td>
<td>58.7</td>
<td>58.6</td>
<td>58.9</td>
<td>59.3</td>
<td>58.7</td>
<td>58.2</td>
<td>58.70</td>
</tr>
</tbody>
</table>

Abbreviations: PTV1, planning target volume 1 (corresponding to PTV51 or PTV54); PTV2, planning target volume 2 (corresponding to PTV60); Conv, conventional.
Figure 4. PreRT CE-T1W, PreRT T2-weighted/FLAIR, and recurrence CE-T1W images with conventional, 1.75-fold, and 2.0-fold CTVs (red, green, and yellow contours, respectively) for patients 4 (A–C) and 11 (D–F). Regions of tumor recurrence (blue contour) anterior and contralateral to contrast enhancement in patient 4 (A) and passing toward the ventricle in patient 11 (D) were not encompassed by the CTV60. The fusion of 1.75- and 2.0-fold Cho/NAA abnormalities with the CTV60 resulted in a target covering a significantly larger proportion of the recurrence.

Figure 5. PreRT CE-T1W, PreRT Cho/NAA map, and recurrence CE-T1W images with 60 Gy IDLs from conventional, 1.75-fold, and 2.0-fold CTVs’ plans (red, green, and yellow contours, respectively) for patients 9 (A–C) and 11 (D–F). The 60 Gy IDLs from the conventional RT plans cover 84.1% and 68.1% of the contrast-enhancing tumor at the time of recurrence (blue contour) in patients 9 and 11, respectively. However, 60 Gy IDLs generated with 1.75-fold (green contours) and 2.00-fold (yellow contours) Cho/NAA thresholds cover a greater proportion of the recurrent tumor (96.1% and 92.4%, in patient 9; 97.6% and 95.3% in patient 11). sMRI-modified 60 Gy IDLs reflect PTV2s generated by a 0.3 cm expansion to the union of the CTV2 with a Cho/NAA-fold threshold.
signal, standardizing abnormalities, and transferring metabolite volumes to RT planning software for target modification alongside conventional images. The lack of such a processing protocol not only makes the use of spectroscopy in RT planning subjective, as clinicians must compare arrayed spectra qualitatively, but also time-consuming and labor-intensive. To overcome these limitations, we used a higher-resolution, whole-brain spectroscopic sequence that gives nominal voxel size of $4.4 \times 4.4 \times 5.6$ mm$^3$, ultimately increasing the utility of spectroscopic data. Furthermore, we established a pipeline to quickly process and integrate normalized sMRI maps into the clinical RT planning workflow.

The addition of Cho/NAA to RT planning considerably modified target volumes and described metabolic abnormalities outside of conventional dose regions. For all but the 1.5-fold threshold, Cho/NAA and conventional CTVs were similar. However, DICE scores were significantly lower for each Cho/NAA threshold, suggesting significant spatial differences from associated CTVs. Taken together, these data suggest that the shape and/or location of the target area is changing without adding a substantial brain volume receiving RT. In addition, the substantial Cho/NAA abnormality beyond the 60 Gy IDL suggests that metabolically active disease does not receive appropriate coverage in conventional RT plans. Similar results were noted in a 2003 report (10), where 21 cm$^3$ of spectroscopic abnormality, on average, fell beyond contrast enhancement in patients with high-grade glioma. Similarly, in a recent study, one-third of the patients receiving RT had metabolically active tumor outside of the CTV60 threshold, many of which expanded beyond 51 Gy and/or 54 Gy IDLs (12). Because the Cho/NAA ratio has been shown to be strongly associated with tumor infiltration in patients with GBM, expansion of the 60 Gy target volume to cover regions that exhibit Cho/NAA elevations may improve local control (13, 26, 27).

The addition of Cho/NAA abnormalities to RT planning resulted in a higher coverage of recurrent contrast-enhancing tumor compared with conventional plans in all cases. In 2 cases, contrast enhancement at recurrence that was Cho/NAA abnormal before treatment fell beyond the 60 Gy IDLs in the conventional plan. Using sMRI-modified plans, expanded 60 Gy IDLs encompassed up to 97.6% of the recurrent tumor in these patients while respecting coverage and organ-at-risk constraints. Targeting plans created from metabolically active regions instead of conventional plans may delay recurrence and should be investigated in larger, prospective trials.

Some weaknesses of this study warrant consideration. Although this pipeline was executed within an RT planning framework, spectral and volumetric processing could be improved. For example, magnetic susceptibility obscures the spectral profile near tissue boundaries, resulting in artifacts. These artifacts can obscure tumor-related abnormalities, making it difficult to accurately define the metabolic margins. Errors in lipid suppression can also yield artifacts; however, none was observed in regions that were used for RT planning. At the signal acquisition level, sophisticated magnetic field shimming protocols are being developed to account for susceptibility changes and attenuate spectral artifacts (30). In addition, we are developing a spectral quality filter to remove spectral artifacts from metabolite maps using machine-learning techniques. Finally, we examined only 3 Cho/NAA-fold levels, whereas the identification of an optimal cutoff for use in RT planning may require evaluating finer Cho/NAA intervals. As such, a sensitivity study using a large number of Cho/NAA thresholds is currently underway to identify the ideal threshold for a future RT dose expansion and escalation study.

CONCLUSIONS

Using a recently developed pipeline, the integration of high-resolution, whole-brain sMRI into RT planning is feasible and resulted in considerably modified RT target volumes that allow the specific targeting of tumor-infiltrated tissue while adhering to normal planning objectives. Such an addition would represent a paradigm shift in the field of image-guided RT away from targeting surrogate markers using tracer-based imaging techniques to targeting imaging biomarkers that describe native biochemical processes. Given the apparent effectiveness of sMRI in identifying regions at high risk for recurrence, this technique shows promise for improving the outcomes for patients with GBM and should be evaluated in larger, prospective clinical trials.

Supplemental Materials

Supplemental Table 1–3: http://dx.doi.org/10.18383/j.tom.2016.00187.sup.01

ACKNOWLEDGMENTS

Equal Contribution: J.S.C and S.K. contributed equally to this work.

This work was supported by the National Institutes of Health grant U01CA172027 (HKS/HIS) and a predoctoral fellowship F31CA180319 (JSC). The spectroscopic sequence and MIDAS were provided by Andrew Maudsley at the University of Miami, and his group has been crucial in the technical components of pipeline optimization.

REFERENCES